Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.

ABSTRACT: AIMS:This preliminary randomized, parallel-group comparative study evaluated the efficacy of ipragliflozin for reduction of small dense low-density lipoprotein cholesterol (sd LDL-C) levels in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS:Sixty-two patients with T2DM (age, 56?±?8 years; hemoglobin A1c levels, 8.1?±?0.9%; BMI, 27.5?±?3.3?kg/m2) were randomly assigned in a 2:1 ratio to receive ipragliflozin (50?mg/day) (treatment group; n?=?40) or continued treatment (control group; n?=?22) for 12 weeks. The primary endpoints were changes in sd LDL-C levels detected using the LipoPhor AS® system; the secondary endpoints included changes in the sd LDL-C/large buoyant LDL-C (lb LDL-C) ratio, a surrogate marker for LDL particle size, and percent changes in routine lipid parameters. RESULTS:The treatment group exhibited a statistically significant reduction from baseline for LDL-C levels (-0.37?mg/dL vs. 14.4?mg/dL, p?=?0.038), sd LDL-C levels (-1.28?mg/dL vs. 2.81?mg/dL, p?=?0.012), and sd LDL-C/lb LDL-C ratio (-3.20% vs. 4.58%, p?=?0.040) compared with the control group. Multiple regression analysis among all subjects revealed change in TG levels (p?=?0.011) and LDL-C levels (p?=?0.024) as well as change in body weight (p?=?0.006) as independent factors contributing to the reduction in sd LDL-C. CONCLUSIONS:Ipragliflozin may have a potential for lowering sd LDL-C levels associated with increasing LDL particle size in Japanese patients with T2DM.

SUBMITTER: Bando Y 

PROVIDER: S-EPMC5644427 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature